|
1
|
Lengauer C, Kinzler KW and Vogelstein B:
Genetic instabilities in human cancers. Nature. 396:643–649. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kinzler KW and Vogelstein B: Lessons from
hereditary colorectal cancer. Cell. 87:159–170. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Iwaizumi M, Shinmura K, Mori H, Yamada H,
Suzuki M, Kitayama Y, Igarashi H, Nakamura T, Suzuki H, Watanabe Y,
et al: Human Sgo1 downregulation leads to chromosomal instability
in colorectal cancer. Gut. 58:249–260. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kahyo T, Iwaizumi M, Shinmura K, Matsuura
S, Nakamura T, Watanabe Y, Yamada H and Sugimura H: A novel
tumor-derived SGOL1 variant causes abnormal mitosis and unstable
chromatid cohesion. Oncogene. 30:4453–4463. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Matsuura S, Kahyo T, Shinmura K, Iwaizumi
M, Yamada H, Funai K, Kobayashi J, Tanahashi M, Niwa H, Ogawa H, et
al: SGOL1 variant B induces abnormal mitosis and resistance to
taxane in non-small cell lung cancers. Sci Rep. 3:30122013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Grady WM: Genomic instability and colon
cancer. Cancer Metastasis Rev. 23:11–27. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Grilley M, Holmes J, Yashar B and Modrich
P: Mechanisms of DNA-mismatch correction. Mutat Res. 236:253–267.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Grady WM and Carethers JM: Genomic and
epigenetic instability in colorectal cancer pathogenesis.
Gastroenterology. 135:1079–1099. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ishikubo T, Nishimura Y, Yamaguchi K,
Khansuwan U, Arai Y, Kobayashi T, Ohkura Y, Hashiguchi Y, Tanaka Y
and Akagi K: The clinical features of rectal cancers with
high-frequency microsatellite instability (MSI-H) in Japanese
males. Cancer Lett. 216:55–62. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kadowaki S, Kakuta M, Takahashi S,
Takahashi A, Arai Y, Nishimura Y, Yatsuoka T, Ooki A, Yamaguchi K,
Matsuo K, et al: Prognostic value of KRAS and BRAF mutations in
curatively resected colorectal cancer. World J Gastroenterol.
21:1275–1283. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lochhead P, Kuchiba A, Imamura Y, Liao X,
Yamauchi M, Nishihara R, Qian ZR, Morikawa T, Shen J, Meyerhardt
JA, et al: Microsatellite instability and BRAF mutation testing in
colorectal cancer prognostication. J Natl Cancer Inst.
105:1151–1156. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nitsche U, Friess H, Agha A, Angele M,
Eckel R, Heitland W, Jauch KW, Krenz D, Nüssler NC, Rau HG, et al:
Prognosis of mucinous and signet-ring cell colorectal cancer in a
population-based cohort. J Cancer Res Clin Oncol. 142:2357–2366.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ribic CM, Sargent DJ, Moore MJ, Thibodeau
SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R,
Shepherd LE, et al: Tumor microsatellite-instability status as a
predictor of benefit from fluorouracil-based adjuvant chemotherapy
for colon cancer. N Engl J Med. 349:247–257. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Carethers JM, Smith EJ, Behling CA, Nguyen
L, Tajima A, Doctolero RT, Cabrera BL, Goel A, Arnold CA, Miyai K,
et al: Use of 5-fluorouracil and survival in patients with
microsatellite-unstable colorectal cancer. Gastroenterology.
126:394–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tajima A, Hess MT, Cabrera BL, Kolodner RD
and Carethers JM: The mismatch repair complex hMutS alpha
recognizes 5-fluorouracil-modified DNA: Implications for
chemosensitivity and resistance. Gastroenterology. 127:1678–1684.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Iwaizumi M, Tseng-Rogenski S and Carethers
JM: DNA mismatch repair proficiency executing 5-fluorouracil
cytotoxicity in colorectal cancer cells. Cancer Biol Ther.
12:756–764. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tajima A, Iwaizumi M, Tseng-Rogenski S,
Cabrera BL and Carethers JM: Both hMutSα and hMutSβ DNA mismatch
repair complexes participate in 5-fluorouracil cytotoxicity. Plos
One. 6:e281172011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Le DT, Durham JN, Smith KN, Wang H,
Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et
al: Mismatch repair deficiency predicts response of solid tumors to
PD-1 blockade. Science. 357:409–413. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Le DT, Uram JN, Wang H, Bartlett BR,
Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et
al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl
J Med. 372:2509–2520. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Boland CR and Goel A: Microsatellite
instability in colorectal cancer. Gastroenterology.
138:2073–2087.e3. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fujiyoshi K, Yamamoto G, Takenoya T,
Takahashi A, Arai Y, Yamada M, Kakuta M, Yamaguchi K, Akagi Y,
Nishimura Y, et al: Metastatic pattern of stage IV colorectal
cancer with high-frequency microsatellite instability as a
prognostic factor. Anticancer Res. 37:239–247. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Guo TA, Wu YC, Tan C, Jin YT, Sheng WQ,
Cai SJ, Liu FQ and Xu Y: Clinicopathologic features and prognostic
value of KRAS, NRAS and BRAF mutations and DNA mismatch repair
status: A single-center retrospective study of 1,834 Chinese
patients with Stage I–IV colorectal cancer. Int J Cancer.
145:1625–1634. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim CG, Ahn JB, Jung M, Beom SH, Kim C,
Kim JH, Heo SJ, Park HS, Kim JH, Kim NK, et al: Effects of
microsatellite instability on recurrence patterns and outcomes in
colorectal cancers. Br J Cancer. 115:25–33. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tanaka S, Kashida H, Saito Y, Yahagi N,
Yamano H, Saito S, Hisabe T, Yao T, Watanabe M, Yoshida M, et al:
JGES guidelines for colorectal endoscopic submucosal
dissection/endoscopic mucosal resection. Dig Endosc. 27:417–434.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu Q, Luo D, Cai S, Li Q and Li X: P-TNM
staging system for colon cancer: Combination of P-stage and AJCC
TNM staging system for improving prognostic prediction and clinical
management. Cancer Manag Res. 10:2303–2314. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kawazoe A, Shitara K, Kuboki Y, Bando H,
Kojima T, Yoshino T, Ohtsu A, Ochiai A, Togashi Y, Nishikawa H, et
al: Clinicopathological features of 22C3 PD-L1 expression with
mismatch repair, Epstein-Barr virus status, and cancer genome
alterations in metastatic gastric cancer. Gastric Cancer. 22:69–76.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shiga H, Ohba R, Matsuhashi T, Jin M,
Kuroha M, Endo K, Moroi R, Kayaba S and Iijima K: Feasibility of
colorectal endoscopic submucosal dissection (ESD) carried out by
endoscopists with no or little experience in gastric ESD. Dig
Endosc. 29 (Suppl 2):58–65. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Iacopini F, Saito Y, Bella A, Gotoda T,
Rigato P, Elisei W, Montagnese F, Iacopini G and Costamagna G:
Colorectal endoscopic submucosal dissection: Predictors and
neoplasm-related gradients of difficulty. Endosc Int Open.
5:E839–E846. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee EJ, Lee JB, Lee SH and Youk EG:
Endoscopic treatment of large colorectal tumors: Comparison of
endoscopic mucosal resection, endoscopic mucosal
resection-precutting, and endoscopic submucosal dissection. Surg
Endosc. 26:2220–2230. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Saito Y, Fukuzawa M, Matsuda T, Fukunaga
S, Sakamoto T, Uraoka T, Nakajima T, Ikehara H, Fu KI, Itoi T, et
al: Clinical outcome of endoscopic submucosal dissection versus
endoscopic mucosal resection of large colorectal tumors as
determined by curative resection. Surg Endosc. 24:343–352. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Benson AB III, Venook AP, Al-Hawary MM,
Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D,
Engstrom PF, et al: NCCN Guidelines Insights: Colon Cancer, Version
2.2018. J Natl Compr Canc Netw. 16:359–369. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nguyen LH, Goel A and Chung DC: Pathways
of colorectal carcinogenesis. Gastroenterology. 158:291–302. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Toyota M, Ahuja N, Ohe-Toyota M, Herman
JG, Baylin SB and Issa JP: CpG island methylator phenotype in
colorectal cancer. Proc Natl Acad Sci USA. 96:8681–8686. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kane MF, Loda M, Gaida GM, Lipman J,
Mishra R, Goldman H, Jessup JM and Kolodner R: Methylation of the
hMLH1 promoter correlates with lack of expression of hMLH1 in
sporadic colon tumors and mismatch repair-defective human tumor
cell lines. Cancer Res. 57:808–811. 1997.PubMed/NCBI
|
|
35
|
Menigatti M, Truninger K, Gebbers JO,
Marbet U, Marra G and Schär P: Normal colorectal mucosa exhibits
sex- and segment-specific susceptibility to DNA methylation at the
hMLH1 and MGMT promoters. Oncogene. 28:899–909. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shen L, Kondo Y, Rosner GL, Xiao L,
Hernandez NS, Vilaythong J, Houlihan PS, Krouse RS, Prasad AR,
Einspahr JG, et al: MGMT promoter methylation and field defect in
sporadic colorectal cancer. J Natl Cancer Inst. 97:1330–1338. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
McCarthy AJ, Serra S and Chetty R:
Traditional serrated adenoma: An overview of pathology and emphasis
on molecular pathogenesis. BMJ Open Gastroenterol. 6:e0003172019.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nazemalhosseini Mojarad E, Kuppen PJ,
Aghdaei HA and Zali MR: The CpG island methylator phenotype (CIMP)
in colorectal cancer. Gastroenterol Hepatol Bed Bench. 6:120–128.
2013.PubMed/NCBI
|
|
39
|
O'Brien MJ, Yang S, Mack C, Xu H, Huang
CS, Mulcahy E, Amorosino M and Farraye FA: Comparison of
microsatellite instability, CpG island methylation phenotype, BRAF
and KRAS status in serrated polyps and traditional adenomas
indicates separate pathways to distinct colorectal carcinoma end
points. Am J Surg Pathol. 30:1491–1501. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Murakami T, Akazawa Y, Yatagai N, Hiromoto
T, Sasahara N, Saito T, Sakamoto N, Nagahara A and Yao T: Molecular
characterization of sessile serrated adenoma/polyps with
dysplasia/carcinoma based on immunohistochemistry, next-generation
sequencing, and microsatellite instability testing: a case series
study. Diagn Pathol. 13:882018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Oono Y, Fu K, Nakamura H, Iriguchi Y,
Yamamura A, Tomino Y, Oda J, Mizutani M, Takayanagi S, Kishi D, et
al: Progression of a sessile serrated adenoma to an early invasive
cancer within 8 months. Dig Dis Sci. 54:906–909. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Asaka S, Arai Y, Nishimura Y, Yamaguchi K,
Ishikubo T, Yatsuoka T, Tanaka Y and Akagi K: Microsatellite
instability-low colorectal cancer acquires a KRAS mutation during
the progression from Dukes' A to Dukes' B. Carcinogenesis.
30:494–499. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ikeda M, Yamanaka T, Yamazaki K, Yamaguchi
K, Muro K, Kusumoto T, Uetake H, Sato T, Kato T, Nishina T, et al:
Validation study of the 12-gene Recurrence Score (RS) in patients
(pts) with stage II and III colon cancer (CC) without adjuvant
chemotherapy; Sunrise Study. Ann Oncol. 26 (Suppl 4):iv1042015.
View Article : Google Scholar
|
